Peptilogics Enrolls First International Patient in RETAIN Trial for Prosthetic Joint Infection Treatment
Peptilogics, a clinical-stage biotech company, has announced the enrollment of the first international patient in the pivotal RETAIN Phase 2/3 trial for zaloganan (PLG0206), a drug candidate designed to treat prosthetic joint infection (PJI). This enrollment took place in the U.K. at Leeds Teaching Hospitals NHS Trust and NIHR Clinical Research Facility: Leeds, marking the first patient outside the U.S. to join the study. Zaloganan is an investigational antimicrobial peptide engineered to target biofilm, the primary driver of serious infections across various implanted medical devices. PJI affects approximately two percent of joint replacements, leading to significant complications and often requiring multiple surgeries. The RETAIN trial is a randomized, double-blind, placebo-controlled study aiming to enroll approximately 240 patients across 50 sites in the U.S., U.K., and Australia.
